Idioma:

Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus

Fogari, R. ; Zoppi, A. ; Maffioli, P. ; Monti, C. ; Lazzari, P. ; Mugellini, A. ; Derosa, G.

Diabetes, obesity & metabolism, 2012-04, Vol.14 (4), p.341-347

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus
Autor: Fogari, R. ; Zoppi, A. ; Maffioli, P. ; Monti, C. ; Lazzari, P. ; Mugellini, A. ; Derosa, G.
Assuntos: Aged ; Amides - administration & dosage ; Amides - pharmacology ; Amlodipine - administration & dosage ; Amlodipine - pharmacology ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - pharmacology ; antihypertensive therapy ; Blood pressure ; Blood Pressure - drug effects ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic Angiopathies - complications ; Diabetic Angiopathies - drug therapy ; Diabetic Angiopathies - physiopathology ; EKG ; Electrocardiography ; Female ; Fumarates - administration & dosage ; Fumarates - pharmacology ; Heart Conduction System - drug effects ; Heart Conduction System - physiopathology ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - physiopathology ; Long QT Syndrome - drug therapy ; Long QT Syndrome - etiology ; Long QT Syndrome - physiopathology ; Male ; Middle Aged ; Placebos ; Prospective Studies ; type 2 diabetes
É parte de: Diabetes, obesity & metabolism, 2012-04, Vol.14 (4), p.341-347
Notas: ArticleID:DOM1535
istex:5E17D358EA6E804DC04E053955D708CC936A1B9A
ark:/67375/WNG-J427ZJ7K-S
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Descrição: Aim: To evaluate the effect of aliskiren compared to amlodipine on QT duration and dispersion in hypertensive patients with type 2 diabetes. Methods: A total of 170 outpatients aged 50–75 years with mild to moderate hypertension (SBP >130 and <180 mmHg and DBP >80 and <100 mmHg) and type 2 diabetes were randomly treated with aliskiren 300 mg or amlodipine 10 mg, both given once daily for 24 weeks, according to a prospective, open label, blinded‐end point, parallel group design. At the end of the placebo run‐in, and after 12, and 24 weeks of treatment blood pressure (BP) measurements (by mercury sphygmomanometer, Korotkoff I and V), plasma biochemistry and a standard 12‐lead surface ECG were evaluated. Results: Both aliskiren and amlodipine significantly reduced systolic blood pressure (SBP)/diastolic blood pressure (DBP) values (−27.2/−14.3 mmHg, p < 0.001 vs. placebo and −27.8/−14.2 mmHg, p < 0.001 vs. placebo, respectively), with no statistical difference between the two drugs. Aliskiren, but not amlodipine, significantly reduced maximum QT interval (QTmax) (−14 ms at 12 weeks and −17 ms at 24 weeks, both p < 0.05 vs. placebo) and corrected QT max (QTc max) (−26 ms and −31 ms, p < 0.01) as well as the dispersion of both QT (−11 ms and −13 ms, p < 0.01) and QTc (−18 ms and −19 ms, p < 0.01). Conclusions: Despite similar BP lowering effect, aliskiren, but not amlodipine, reduced QT duration and dispersion, which might be related to the ability of aliskiren to interfere with mechanisms underlying myocardial electrical instability in the heart of diabetic hypertensive patients.
Editor: Oxford, UK: Blackwell Publishing Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus

Fogari, R. ; Zoppi, A. ; Maffioli, P. ; Monti, C. ; Lazzari, P. ; Mugellini, A. ; Derosa, G.

Oxford, UK: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.